C4 Therapeutics reports Q3 2026 financials and updates on development programs
C4 Therapeutics reported third quarter financial results and highlighted recent achievements in Phase 2 MOMENTUM and Phase 1b trials, showing progress towards data publication in late 2026 and enrollment goals for 2027, which underscores ongoing clinical advancement for its cemsidomide candidate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed